EU Panel OKs Glasdegib for AML and Luspatercept for MDS EU Panel OKs Glasdegib for AML and Luspatercept for MDS
Glasdegib has been recommended for approval in Europe for acute myeloid leukemia, and luspatercept has been recommended for anemia associated with myelodysplastic syndromes.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 1, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Grants Priority Review to CC-486 for the Treatment of Acute Myeloid Leukemia
The FDA granted priority review to a new drug application for CC-486 for the maintenance treatment of adult patients with acute myeloid leukemia based on efficacy and safety results from the pivotal phase III QUAZAR AML-001 study. (Source: CancerNetwork)
Source: CancerNetwork - May 1, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb ’s Application for CC-486 for Maintenance Treatment of Adult Patients in Remission with Acute Myeloid Leukemia
PRINCETON, N.J.--(BUSINESS WIRE) May 1, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for CC-486, an investigational oral hypomethylating agent,... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 1, 2020 Category: Drugs & Pharmacology Source Type: news
Smoking Tied to Inferior Survival in Acute Myeloid Leukemia
WEDNESDAY, April 29, 2020 -- Smoking status is an important patient-related prognostic factor for outcome in patients with acute myeloid leukemia (AML) treated with intensive chemotherapy, according to a study published online April 21 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 29, 2020 Category: Pharmaceuticals Source Type: news
EHA Webinar Addresses Treating AML Patients With COVID-19 EHA Webinar Addresses Treating AML Patients With COVID-19
A hematologist in Italy shared his personal experience regarding COVID-19 and the care of acute myeloid leukemia (AML) patients during a webinar hosted by the European Hematology Association.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 29, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Drug prevents severe cardiac events in children undergoing chemotherapy for AML
(Children's Hospital of Philadelphia) The cardioprotective drug dexrazoxane preserved cardiac function in pediatric patients undergoing chemotherapy for acute myeloid leukemia (AML) without compromising overall patient survival and potentially improving it, according to a new study by researchers at Children's Hospital of Philadelphia (CHOP). The results suggest dexrazoxane should be considered for cardioprotection in all pediatric patients undergoing standard chemotherapy for AML. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 28, 2020 Category: Cancer & Oncology Source Type: news
Treatment Approaches in Acute Myeloid Leukemia Treatment Approaches in Acute Myeloid Leukemia
Dr James Foran speaks with Dr David Henry about his preferred treatment algorithm for patients with AML.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news
Three-Drug Combo'Highly Effective' in Acute Myeloid Leukemia Three-Drug Combo'Highly Effective' in Acute Myeloid Leukemia
A new combination of old drugs has shown ' unexpectedly ' higher response rates in patients with relapsed/refractory acute myeloid leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 31, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia
Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile of the...
Source: Roche Investor Update - March 23, 2020 Category: Pharmaceuticals Source Type: news
Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia
Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile of the...
Source: Roche Media News - March 23, 2020 Category: Pharmaceuticals Source Type: news
Venetoclax with Azacytidine Improved Overall Survival for Patients with AML
Genentech recently announced their phase III study resulted in improved overall survival and composite complete remission rates for patients with previously untreated acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - March 23, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Oncotarget Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity
(Impact Journals LLC) Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.Dr. Takeshi Isoyama from Daiichi Sankyo Co., Ltd. said, " FMS like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase expressed by acute myeloid leukemia (AML) cells in 70% to 90% of patients. " (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 20, 2020 Category: International Medicine & Public Health Source Type: news
Venetoclax and Chemo: A'Step Forward' for Children With r/r AML Venetoclax and Chemo: A'Step Forward' for Children With r/r AML
Adding the targeted therapy to chemotherapy has shown good results in pediatric patients with relapsed or refractory acute myeloid leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 17, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Use of Post-HSCT Cyclophosphamide Improves Transplantation Outcomes for AML/MDS
Hematopoietic stem cell transplantation (HSCT) with prior use of checkpoint inhibitors was found to be feasible in patients with acute myeloid leukemia and/or myelodysplastic syndromes and the use of post-HSCT cyclophosphamide as graft-versus host disease prophylaxis improves outcomes. (Source: CancerNetwork)
Source: CancerNetwork - March 12, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
2.45 m to investigate leukaemia causes and therapies
(European Molecular Biology Laboratory) The Heidelberg-based LeukoSyStem consortium investigates leukemia stem cells in acute myeloid leukemia. The German Federal Ministry of Education and Research financially supports this collaboration between Heidelberg University Hospital, HI-STEM gGmbH, the German Cancer Research Center and EMBL. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 11, 2020 Category: International Medicine & Public Health Source Type: news
